SYNGR4

Across TCGA pan-cancer cohorts, SYNGR4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SYNGR4 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SYNGR4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SYNGR4 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

GBM, LSCC, and LUAD are the cancer types where SYNGR4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.276	0.509	.012	9	view →
LSCC	DFS	Median	All	0.918	0.634	.019	5	view →
LUAD	OS	Median	All	1.000	0.667	.014	4	view →
UCEC	DFS	Median	All	0.908	1.000	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SYNGR4–GBM (OS)

Open the GBM breakdown →